Chronic Obstructive Pulmonary Diseases:Journal of the COPD Foundation

Running Head: Editorial: Fibrinogen and COPD

Funding Support: Not applicable

Abbreviations: COPD Biomarker Qualification Consortium, CBQC; hazard ratio, HR; confidence interval, CI; cardiovascular disease, CVD

Citation: Faner R, Agusti A. Fibrinogen and COPD: Now what?

J COPD F. 2015; 2(1): 1-3. doi:


It is often said that chronic obstructive pulmonary disease (COPD) is a complex and heterogeneous disease.1 Not that often, however, are the meanings of complex and heterogeneous defined. Complex means that COPD has different intra and extra-pulmonary components, both at the molecular, structural, functional and clinical levels, whereas heterogeneous means that not all these components are present in all patients or, in a given patient, that these components may change over time.2 Given that these different domains of the disease can influence its clinical course and may require specific treatment, it follows that it is important to identify and validate biomarkers that inform on their presence or absence, as well a on their potential response to treatment.3,4 In this issue of Chronic Obstructive Pulmonary Diseases: Journal of COPD Foundation, Mannino et al5 present evidence to qualify fibrinogen as a biomarker for risk stratification of COPD patients. This is an important report not only because of its scientific content but also because of the way it has been developed, since it has been produced by the COPD Biomarker Qualification Consortium (CBQC),6 a successful example of public-private partnership to be exported to other areas of medical research.7

Fibrinogen is an acute phase soluble plasma glycoprotein and the principal protein of vertebrate blood clotting. 8 Normal fibrinogen levels in blood are between 150 and 350 mg/dL8 . Mannino et alused a cohort of 6376 COPD patients from publically and industry funded studies in the CBQC to explore the value of fibrinogen values higher than 350 mg/dL to predict the risk of hospitalizations from exacerbations and death.5 They found that almost half of the patients had increased fibrinogen values (≥ 350 mg/dL) and that this was associated with an increased risk of future hospitalization because of COPD exacerbations (hazard ratio (HR): 1.64; 95% confidence interval (CI): 1.39–1.93) and all-cause mortality (HR: 1.94; 95% CI: 1.62–2.31). 5 Authors conclude that these results support the use of high fibrinogen values to identify high risk COPD patients both in clinical practice and as a way to enrich for this phenotype in future clinical trials in COPD.5

These results are in line with other previous studies showing that a proportion of, but not all, COPD patients have evidence of persistent systemic inflammation (including fibrinogen) and that this is associated with poor outcomes.9 As with any good research study, though, this particular one5 also raises more questions than offers answers. First, the origin of systemic inflammation in some patients with COPD continues to be obscure.10 Second, fibrinogen is a well established biomarker of cardiovascular disease (CVD),11 and CVDs are one of the main (if not the main) cause of death in COPD and a frequent comorbidity in these patients.12,13 Although authors report on all-cause mortality,5 it is not surprising therefore, that high fibrinogen levels predict death in COPD. It is less straightforward, though, that high fibrinogen levels predict the risk of hospitalization because of an exacerbation of COPD. Although fibrinogen levels can increase during exacerbations of COPD,8 it is unclear why high levels when clinically stable should predict the risk of severe exacerbation, unless we consider that these episodes might involve a cardiovascular component.14 Alternatively, it is also plausible that systemic fibrinogen levels might mirror an enhanced pulmonary production of this protein15 since CR3, a complement receptor that recognizes bacterial antigens and is present on neutrophils, NK cells, and macrophages, binds fibrinogen,16 and thus provides a potential link of fibrinogen levels with pulmonary inflammation. Third, what can we do to treat these patients and reduce their future risk of hospitalization and death is also unclear. Yet, several alternatives may be considered. On the one hand, optimal treatment of COPD is unavoidable.1 On the other, proper treatment of CVD risk factors are also a must. In this context, although statins do not reduce exacerbations of COPD in patients without a CV indication for them,17 their beneficial effect in the rest of COPD patients (actually the majority) is well established.18,19 The effect of other potential therapeutic alternatives for COPD patients with systemic inflammation, including anti-inflammatory treatment, regular physical activity, dietary changes and/or anti-oxidants agents, among others, deserve further research. Finally, the results of this study5 support the proposal of a control panel for the management of COPD,20 where the identification, treatment and monitoring of several COPD treatable traits, including validated biomarkers such as fibrinogen, may allow us to better understand the complexity and heterogeneity of COPD and, as a result, progress towards personalized medicine in these patients. 2,21

Online Supplement

1. Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease, GOLD Executive Summary. Am.J Respir Crit Care Med . 2013;187(4):347-365. doi:

2. Agusti,A. The path to personalized medicine in COPD. Thorax. 2014; 69:857-864. doi:

3. Agusti A, Sin DD. Biomarkers in COPD. Clin.Chest Med. 2014; 35 (1):131-141. doi:

4. Faner R, Tal-Singer R, Riley JH, et al. Lessons from ECLIPSE: a review of COPD biomarkers. Thorax.2014; 69 (7):672. doi:

5. Mannino DM, Tal-Singer R, Lomas DA, et al. Plasma fibrinogen as a biomarker for mortality and hospitalized exacerbations in people with COPD. J COPD F. 2015; 2(1): ADD PAGE NUMBERS HERE(In press)

6. Casaburi R, Celli B, Crapo J, et al. The COPD Biomarker Qualification Consortium (CBQC). COPD .2013; 10 (3):367-377. doi:

7. Crowley WF, Jr., Sherwood L, Salber P, et al. Clinical research in the United States at a crossroads: proposal for a novel public-private partnership to establish a national clinical research enterprise. JAMA. 2004; 291(9):1120-1126. doi:

8. Duvoix A, Dickens J, Haq I, et al. Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease. Thorax. 2013. 68(7):670-676. doi:

9. Agusti A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: A Novel Phenotype. PLoS ONE.2012; 7:e37483. doi:

10. Agusti A. Systemic effects of chronic bstructive pulmonary disease: what we know and what we don't know (but should). Proc Ame Thorac Society. 2007; 4 (7):522-525. doi:

11. The Emerging Risk Factors Collaboration. C-Reactive Protein, Fibrinogen, and Cardiovascular Disease Prediction. New Eng J Med. 2012; 367:1310-1320. doi:

12. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: role of comorbidities. Eur Respir J . 2006; 28(6):1245-1257. doi:

13. Divo M, Cote C, de Torres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012; 186 (2):155-161. doi:

14. Fabbri LM, Beghe B, Agusti A. Cardiovascular mechanisms of death in severe COPD exacerbation: time to think and act beyond guidelines. Thorax. 2011; 66 (9):745-747. doi:

15. Papaioannou, AI, Mazioti A, Kiropoulos T, et al. Systemic and airway inflammation and the presence of emphysema in patients with COPD. Respiratory Medicine. 2010; 104(2):275-282. doi:

16. Wright SD, Weitz JI, Huang AJ, Levin SM, Silverstein SC, Loike JD. 1988. Complement receptor type three (CD11b/CD18) of human polymorphonuclear leukocytes recognizes fibrinogen. PNAS. 1988: 85(20):7734-7738. doi:

17. Criner G J, Connett JE, Aaron SD, et al. Simvastatin for the Prevention of Exacerbations in Moderate-to-Severe COPD. New Eng J Med. 2014 370:2201-2210. doi:

18. Ingebrigtsen TS, Marott JL, Nordestgaard BG, Lange P, Hallas J Vestbo J. Statin use and exacerbations in individuals with chronic obstructive pulmonary disease. Thorax. 2014; 70:33-40. doi:

19. Young RP, Hopkins RJ, Agusti A. 2014. Statins as adjunct therapy in COPD: how do we cope after STATCOPE? Thorax. 2014; 69:891-894. doi:

20. Agusti A, MacNee W. The COPD control panel: towards personalised medicine in COPD. Thorax. 2013; 68:687-690. doi:

21. Agusti A, Anto JM, Auffray C, et al. Personalized respiratory medicine: Exploring the horizon, addressing the issues [published online ahead of print, December 22, 2014. Am J Respir Crit Care Med . 2014. doi:

Posted in: Editorial, Volume 2 | Number 1

Bookmark the Permalink

Share This Article

E-mail this article to a friend